Drug class in one race
EGFR + HER3 drugs for HR+/HER2- Metastatic Breast Cancer
2 tracked EGFR + HER3 drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the EGFR + HER3 page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
2 Phase 3